Literature DB >> 29942395

Contribution of Radionuclide Theranostics for Managing Intractable Malignancies.

Byeong-Cheol Ahn1.   

Abstract

Entities:  

Year:  2018        PMID： 29942395      PMCID： PMC5995783          DOI： 10.1007/s13139-018-0526-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


× No keyword cloud information.
  5 in total

1.  Nuclear Medicine in the Era of Precision Medicine.

Authors:  Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2017-03-28

Review 2.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 3.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

Review 4.  Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.

Authors:  Byeong-Cheol Ahn
Journal:  Biomed Res Int       Date:  2016-04-28       Impact factor: 3.411

Review 5.  Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy.

Authors:  Chae Moon Hong; Byeong-Cheol Ahn
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-12       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.